Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder

Psychiatric disorders such as schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) arise from complex interactions between genetic and environmental factors. Common genetic variants associated with multiple psychiatric disorders suggest that shared genetic architecture could contribute to divergent clinical syndromes. To evaluate shared transcriptional alterations across connected brain regions, Affymetrix microarrays were used to profile postmortem dorsolateral prefrontal cortex (DLPFC), hippocampus, and associative striatum from 19 well-matched tetrads of subjects with SCZ, BD, MDD, or unaffected controls. SCZ subjects showed a substantial burden of differentially expressed genes across all examined brain regions with the greatest effects in hippocampus, whereas BD and MDD showed less robust alterations. Pathway analysis of transcriptional profiles compared across diagnoses demonstrated commonly enriched pathways between all three disorders in hippocampus, significant overlap between SCZ and BD in DLPFC, but no significant overlap of enriched pathways between disorders in striatum. SCZ samples showed increased expression of transcripts associated with inflammation across all brain regions examined, which was not evident in BD or MDD, or in rat brain following chronic dosing with antipsychotic drugs. Several markers of inflammation were confirmed by RT-PCR in hippocampus, including S100A8/9, IL-6, MAFF, APOLD1, IFITM3, and BAG3. A cytokine ELISA panel showed significant increases in IL-2 and IL-12p70 protein content in hippocampal tissue collected from same SCZ subjects when compared to matched control subjects. These data suggest an overlapping subset of dysregulated pathways across psychiatric disorders; however, a widespread increase in inflammation appears to be a specific feature of the SCZ brain and is not likely to be attributable to chronic antipsychotic drug treatment.

[1]  T. Kishimoto,et al.  Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental deficits in a 22q11 deletion syndrome mouse model , 2013, Proceedings of the National Academy of Sciences.

[2]  D. Volk,et al.  Chemokine receptors and cortical interneuron dysfunction in schizophrenia , 2015, Schizophrenia Research.

[3]  Torfi Sigurdsson,et al.  Hippocampal-Prefrontal Interactions in Cognition, Behavior and Psychiatric Disease , 2016, Front. Syst. Neurosci..

[4]  S. Henriksen,et al.  Profound increase in sensitivity to glutamatergic‐ but not cholinergic agonist‐induced seizures in transgenic mice with astrocyte production of IL‐6 , 2003, Journal of neuroscience research.

[5]  R. Ophoff,et al.  Transcriptome-wide mega-analyses reveal joint dysregulation of immunologic genes and transcription regulators in brain and blood in schizophrenia , 2016, Schizophrenia Research.

[6]  Gil D. Hoftman,et al.  Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia , 2017, Biological Psychiatry.

[7]  M. Cairns,et al.  Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia , 2013, Molecular Psychiatry.

[8]  D. Rujescu,et al.  Systems biology and complex neurobehavioral traits. , 2008, Pharmacopsychiatry.

[9]  Johan Kreuger,et al.  Inflammation-related genes up-regulated in schizophrenia brains , 2007 .

[10]  E. Fama,et al.  Migration , 2007 .

[11]  R Freedman,et al.  Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. , 2005, Brain research. Molecular brain research.

[12]  S. Bove,et al.  Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder , 2015, Neurobiology of Disease.

[13]  J. Glausier,et al.  Lower Glutamic Acid Decarboxylase 65-kDa Isoform Messenger RNA and Protein Levels in the Prefrontal Cortex in Schizoaffective Disorder but Not Schizophrenia , 2015, Biological Psychiatry.

[14]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[15]  N. Brandon,et al.  Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes , 2012, Translational Psychiatry.

[16]  M. Cuénod,et al.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? , 2016, Schizophrenia Research.

[17]  Martin J. Schmidt,et al.  Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes , 2014, Molecular Psychiatry.

[18]  A. Carvalho,et al.  Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review , 2012, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[19]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[20]  Marquis P. Vawter,et al.  The first decade and beyond of transcriptional profiling in schizophrenia , 2012, Neurobiology of Disease.

[21]  A. Sampson,et al.  Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia , 2003, The Journal of Neuroscience.

[22]  S. Horvath,et al.  Statistical Applications in Genetics and Molecular Biology , 2011 .

[23]  J. Rubenstein,et al.  CXCR4 and CXCR7 Have Distinct Functions in Regulating Interneuron Migration , 2011, Neuron.

[24]  Urs Meyer,et al.  Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia , 2005, Neuroscience & Biobehavioral Reviews.

[25]  Pat Levitt,et al.  Molecular Evidence for Increased Expression of Genes Related to Immune and Chaperone Function in the Prefrontal Cortex in Schizophrenia , 2007, Biological Psychiatry.

[26]  V. Mondelli,et al.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? , 2015, Psychopharmacology.

[27]  E. Ginns,et al.  Molecular Determinants of Dysregulated GABAergic Gene Expression in the Prefrontal Cortex of Subjects with Schizophrenia , 2009, Biological Psychiatry.

[28]  E. Hoshi.  Cortico-basal ganglia networks subserving goal-directed behavior mediated by conditional visuo-goal association , 2013, Front. Neural Circuits.

[29]  S. Haber,et al.  The Reward Circuit: Linking Primate Anatomy and Human Imaging , 2010, Neuropsychopharmacology.

[30]  A. Mechelli,et al.  Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. , 2009, Brain : a journal of neurology.

[31]  Benjamin W. H. Lim,et al.  Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars , 2007, Proceedings of the National Academy of Sciences.

[32]  J. Sebat,et al.  High Frequencies of De Novo CNVs in Bipolar Disorder and Schizophrenia , 2011, Neuron.

[33]  Stella Dracheva,et al.  Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. , 2007, The international journal of neuropsychopharmacology.

[34]  A. Sampson,et al.  Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.

[35]  D. Kelly,et al.  A review of anti-inflammatory agents for symptoms of schizophrenia , 2013, Journal of psychopharmacology.

[36]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[37]  H. Lane,et al.  Glutamate signaling in the pathophysiology and therapy of schizophrenia , 2012, Pharmacology Biochemistry and Behavior.

[38]  E. Miller,et al.  An integrative theory of prefrontal cortex function. , 2001, Annual review of neuroscience.

[39]  A. Meyer-Lindenberg,et al.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.

[40]  D. Lewis,et al.  GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia , 2011, Neural plasticity.

[41]  V. Haroutunian,et al.  Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.

[42]  M. Webster,et al.  Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains , 2005, Biological Psychiatry.

[43]  P. Patterson,et al.  Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development , 2013, Brain, Behavior, and Immunity.

[44]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[45]  Alan S. Brown,et al.  Maternal infection and schizophrenia: implications for prevention. , 2011, Schizophrenia bulletin.

[46]  F. Middleton,et al.  Altered Expression of 14-3-3 Genes in the Prefrontal Cortex of Subjects with Schizophrenia , 2005, Neuropsychopharmacology.

[47]  H. M. Morris,et al.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia , 2008, Molecular Psychiatry.

[48]  M. Behrens,et al.  Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia , 2008, The Journal of Neuroscience.

[49]  Stephan Eliez,et al.  Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. , 2014, The American journal of psychiatry.

[50]  D. Volk,et al.  Molecular mechanisms and timing of cortical immune activation in schizophrenia. , 2015, The American journal of psychiatry.

[51]  A. Sawa,et al.  Increased stereotypy in conditional Cxcr4 knockout mice , 2016, Neuroscience Research.

[52]  Peter Falkai,et al.  Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. , 2010, Journal of psychiatric research.

[53]  M. Webster,et al.  Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia , 2013, Translational Psychiatry.

[54]  S. Escot,et al.  SDF1-CXCR4 signaling: A new player involved in DiGeorge/22q11-deletion syndrome , 2016, Rare diseases.

[55]  Jianxin Shi,et al.  Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs , 2013, Nature Genetics.

[56]  J. Feldon,et al.  Stress in Puberty Unmasks Latent Neuropathological Consequences of Prenatal Immune Activation in Mice , 2013, Science.

[57]  Yogesh K. Dwivedi,et al.  Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. , 2000, Archives of general psychiatry.

[58]  Andrew L. Lemire,et al.  Deficient Hippocampal Neuron Expression of Proteasome, Ubiquitin, and Mitochondrial Genes in Multiple Schizophrenia Cohorts , 2005, Biological Psychiatry.

[59]  M. Barnes,et al.  Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function , 2009, Molecular Psychiatry.

[60]  M. Webster,et al.  Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. , 2010, The American journal of psychiatry.

[61]  Aiqing He,et al.  Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder , 2014, Molecular Psychiatry.

[62]  S. Kapur,et al.  Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[63]  H. M. Morris,et al.  Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. , 2008, Cerebral cortex.

[64]  C. Davies,et al.  Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia , 2011, Journal of neuroscience research.

[65]  A. Roberts,et al.  IL-6 Mediated Degeneration of Forebrain GABAergic Interneurons and Cognitive Impairment in Aged Mice through Activation of Neuronal NADPH Oxidase , 2009, PloS one.

[66]  A. LaMantia,et al.  Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome , 2012, Proceedings of the National Academy of Sciences.

[67]  Ben A. Barres,et al.  Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner , 2012, Neuron.